The international STRIDE trial evaluated the efficacy of semaglutide in improving walking ability in individuals with peripheral artery disease (PAD) and type 2 diabetes. The results revealed a significant improvement in maximum walking distance, pain-free walking distance, and quality of life in patients receiving semaglutide compared to a placebo, suggesting its potential as a treatment option for functional impairment in PAD.

Source: The Lancet